ArticleScientific reports2025
Advanced eco-friendly spectrophotometric analysis for Nebivolol, Valsartan, and related impurity with comprehensive environmental impact assessment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eco-friendly spectrophotometric determination of moxifloxacin in pharmaceutical dosage form via ion-pair complexation with erythrosine B.BMC chemistry · 2026Article
- Simultaneous spectrophotometric eco-friendly analysis of triple-drug H.pylori regimen (Vonoprazan, Amoxicillin, Metronidazole) for quality control and in vitro dissolution testing.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, one of the main priorities for analysts is creating more sustainable and environmentally friendly methods for pharmaceutical analysis. In this context, three innovative spectrophotometric techniques, using tri-colored (green, blue, and white), were optimized and developed to simultaneously assess two antihypertensive drugs, Nebivolol hydrochloride (NEB) and Valsartan (VAL), in the presence of synthetic precursor impurity of Valsartan (Valsartan Desvaleryl, VAL-D), which is the main acidic degradation product. The methods employed, including the double divisor-ratio spectra derivative spectrophotometric method, the dual-wavelength in ratio spectrum method, and the H-point derivative ratio method, displayed a good linear range of 2.5-70 µg/mL, 10-50 µg/mL, and 10-70 µg/mL for NEB, VAL, and VAL-D, respectively. Assessment of greenness was implemented to the established methods using the analytical Eco-Scale scoring, analytical greenness metric (AGREE), and the green analytical process index (GAPI). The concepts of blueness assessment using the recently introduced Blue Applicability Grade Index (BAGI tool) and whiteness assessment using the Red Green Blue 12 (RGB 12 tool) were also applied. The proposed methods were validated as per ICH guidelines and verified to be accurate. Statistical analysis was performed to ensure the validity of methods concerning published methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.